Switching now to our technology platforms and starting with OmniAb. Our OmniAb antibody discovery platform continues to grow and rapidly drive the expansion of our portfolio of partnerships. There are now 12 distinct Phase 1 and Phase 2 studies under way or recently completed with OmniAb derived antibodies and we expect that number to grow with more partners preparing to start new clinical trials. The majority of these antibodies are for oncology indications and one is in the autoimmune area, since that time, we purchased the Omni-technology just over three years ago, the number of partners accessing OmniAb antibodies has nearly tripled.